Mind
PMOS is one of the most common endocrine conditions affecting women of reproductive age, yet it remains widely misunderstood, by the women living with it, and too often by the clinicians managing it. The role of stress in this condition sits at the center of much of that confusion.
Women are frequently told that their PMOS would improve if they just reduced their stress. The implication is that psychological distress caused the condition, or that managing emotions is the primary treatment pathway. Neither of these positions is well-supported by the current evidence.
This editorial works through what the research actually shows about the relationship between psychological stress, cortisol, HPA axis dysregulation, and the hormonal profile of PMOS, so that you can understand the biology rather than internalise a narrative of personal failure.
PMOS affects an estimated 8 to 13 percent of women of reproductive age worldwide. It is defined by a combination of features, excess androgen production, irregular ovulation, and polycystic ovarian morphology, and its causes are multifactorial, with genetics playing a significant role.
Stress does not cause PMOS in any direct or straightforward sense. What the research does suggest is that chronic psychological stress can influence the severity of symptoms in women who already have the condition, and that the HPA axis, the body's primary stress-response system, interacts with the reproductive hormone axis in ways that remain an active area of investigation.
The distinction between triggering a condition and exacerbating an existing one is clinically and personally significant. Women with PMOS deserve to understand that distinction clearly.
Cortisol, the primary stress hormone, can stimulate androgen production in the adrenal glands, and adrenal androgens contribute to the hyperandrogenism seen in many women with PMOS. However, research has not established that stress-driven cortisol elevation is sufficient to produce PMOS in women without underlying susceptibility.
“Insulin resistance is present in the majority of women with PMOS regardless of body weight, and its link to androgen excess is better understood than any stress pathway.”
Studies examining the HPA axis in women with PMOS show mixed results. Some find elevated basal cortisol; others find altered cortisol reactivity to stress challenges; others find no significant difference compared to controls. The heterogeneity of PMOS as a condition makes population-level generalizations inherently unreliable.
The narrative that stress causes PMOS places responsibility on the individual woman for a condition that is primarily biological in origin. It can lead women to delay seeking clinical management while pursuing stress-reduction strategies as a primary intervention, and it can generate significant shame when those efforts do not resolve their symptoms.
Understanding that PMOS is a complex, multifactorial condition, one in which stress may play a modulating role but not a causal one, allows women to engage with evidence-based treatment, which includes metabolic management, hormonal regulation, and psychological support, without misplacing the locus of responsibility.
PMOS is one of the conditions where the gap between what women are told and what the evidence actually shows is most consequential. The stress-causes-PMOS narrative is not just scientifically imprecise, it has real effects on how women understand their own bodies and how aggressively they advocate for clinical care.
The evidence points to a condition rooted in genetics and metabolic biology, with a meaningful psychological dimension that runs in both directions. Women with PMOS deserve a clinical conversation that reflects that complexity, and an evidence base translated in a way that supports informed self-advocacy rather than self-blame.